Merck & Co., Inc.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Merck & Co., Inc. reported 13 stock positions worth $258.0 million. Its top holding was Moderna (MRNA) at 37.2% of the portfolio, followed by Personalis (PSNL, 31.5%) and Kymera Therapeutics (KYMR, 12.0%).
- Most Recent 13F
- Q2 2026
- Location
- RAHWAY, NJ
- CIK
- 0000310158
- Portfolio Value
- $258.0M (Q4 2024)
- SEC Filing
- 0000895345-25-000055 ↗ filed Feb 14, 2025
Holdings Value
Holdings 13 stocks · $258.0M
| MRNA Moderna Inc. | 37.19% | 2,308,190 | $96.0M | — |
| PSNL Personalis Inc. | 31.46% | 14,044,943 | $81.2M | — |
| KYMR Kymera Therapeutics Inc. | 12.04% | 772,165 | $31.1M | — |
| ENTRADA THERAPEUTICS INC | 11.66% | 1,739,768 | $30.1M | — |
| ALEC Alector Inc. | 2.60% | 3,545,719 | $6.7M | — |
| STRO Sutro Biopharma Inc. Com SHS | 1.94% | 2,723,509 | $5.0M | — |
| ABSI Absci Corp. | 1.01% | 998,163 | $2.6M | — |
| VRDN Viridian Therapeutics Inc. | 0.69% | 93,414 | $1.8M | — |
| XLO Xilio Therapeutics Inc. | 0.55% | 1,483,758 | $1.4M | — |
| LVTX Lava Therapeutics NV | 0.42% | 1,149,345 | $1.1M | — |
| CARM Carisma Therapeutics Inc. | 0.24% | 1,473,240 | $617K | — |
| EVAX Evaxion Biotech A/S | 0.18% | 542,279 | $458K | — |
| NEUP Neuphoria Therapeutics Inc. | 0.01% | 10,027 | $34K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $526.4M | PSNL, MRNA, KYMR, AKTS, EIKN |
| Q1 2026 | 14 | $349.4M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN |
| Q4 2025 | 12 | $276.3M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX |
| Q3 2025 | 13 | $228.0M | PSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC |
| Q2 2025 | 13 | $215.6M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q1 2025 | 12 | $164.3M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q4 2024 | 13 | $258.0M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |